Galapagos (NasdaqGS:GLPG) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAaron Cox - CFOBrian Abrahams - Managing Director and Co-Head of Biotechnology ResearchHenry Gosebruch - CEOSean McCutcheon - Director, BiotechnologySofie Van Gijsel - Head of Investor RelationsConference Call ParticipantsDelphine Laoui - Senior Research AnalystMatthias Danne - AnalystPhilip Nadeau - AnalystOperatorGood day. Thank you for standing by. Welcome to the Galapagos Year-End 2025 Financial Results Con ...

Galapagos (NasdaqGS:GLPG) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker5Good day. Thank you for standing by. Welcome to the Galapagos Year-End 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one and one on your telephone. You will hear an automated message advising your hand is raised. To withdraw your ...

Fiscal Year 2025 Results Presentation, February 24, 2026 Forward-Looking Statements This presentation contains "forward looking statements," all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "vision," " progress," "believe," "anticipate," "plan," "continue," "forward," "goal," "should," "expect," "outlook," "estimate," "next," "encouraging," " aim," and "will," and "initiate" as well as any similar expressio ...

Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business development-led growth strategy 2026 year-end cash expected to be in the range of €2.775 to €2.850 billion, with reduced cell therapy one-time restructuring cash costs of €25 million to an updated range of €125 to €175 million Management to host conference call tomorrow, February 24, 2026, at 14: ...

Core Insights - Galapagos NV has appointed Dr. Paulo Fontoura as a Non-Executive Independent Director to its Board of Directors, effective February 9, 2026, replacing Dr. Susanne Schaffert [1] - The appointment is expected to enhance the Board's strategic guidance capabilities as the company explores transformative business development opportunities [1][2] Company Overview - Galapagos is focused on disciplined growth and advancing innovative medicines for patients while delivering long-term value for shareholders [2] - The company is entering a new phase with a clear strategic focus [2] Dr. Paulo Fontoura's Background - Dr. Fontoura has 20 years of experience in the pharmaceutical industry, with expertise in neurology, immunology, ophthalmology, and rare diseases [2] - He previously served as Chief Medical Officer at Xaira and held a senior position at Roche, where he led clinical development and contributed to the launch of multiple breakthrough therapies [2] - Dr. Fontoura has academic credentials including an MD and PhD in Neuroimmunology from the New University of Lisbon and a postdoctoral fellowship at Stanford University [2]

Core Insights - Artiva Biotherapeutics, Inc. has appointed Elaine Sorg to its Board of Directors, bringing over 35 years of experience in the biopharmaceutical industry, particularly in immunology therapies [1][2] - The company is preparing to share clinical activity data from its AlloNK regimen for rheumatoid arthritis and engage with the FDA for a registrational trial, indicating a significant phase in its development [2] - AlloNK is positioned as a potentially transformative treatment for autoimmune diseases, with a focus on B-cell depletion and improved efficacy compared to existing therapies [2][4] Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing cell therapies for autoimmune diseases and cancers, with its lead program being AlloNK, a non-genetically modified NK cell therapy [4][5] - The company was founded in 2019 as a spin-out from GC Cell, acquiring exclusive worldwide rights to NK cell manufacturing technology [4] Leadership Experience - Elaine Sorg has held senior executive roles at major pharmaceutical companies, including AbbVie and Eli Lilly, where she was instrumental in the commercialization of key immunology products [2][3] - Her experience includes leading U.S. commercialization efforts for a broad portfolio of medicines and overseeing major autoimmune disease brands [2][3]

Core Viewpoint - Bank of America Corporation has crossed the 5% threshold of voting rights in Galapagos NV, indicating a significant increase in its stake in the company as of February 9, 2026 [1][6]. Summary by Relevant Sections Voting Rights - As of February 11, 2026, Bank of America Corporation, including its affiliates, holds 104,522 voting rights and 3,415,894 equivalent financial instruments, totaling 5.34% of Galapagos' 65,897,071 outstanding shares [2][6]. - The direct voting rights after the transaction are 0.16%, while the equivalent financial instruments account for 5.18%, leading to a total of 5.34% voting rights [3]. Transaction Details - The threshold was crossed on February 9, 2026, with the notification received on February 11, 2026 [6]. - The acquisition was due to the purchase of financial instruments treated as voting securities [6]. Breakdown of Voting Rights - The previous notification indicated no voting rights held by Bank of America Corporation, while after the transaction, the total voting rights held is 104,522, representing 0.16% [5]. - The breakdown of equivalent financial instruments includes various types such as rights to recall and swaps, with a total of 3,415,894 equivalent financial instruments representing 5.18% [7]. Total Voting Rights - The combined total of voting rights and equivalent financial instruments held by Bank of America Corporation is 3,520,416, which constitutes 5.34% of Galapagos' voting rights [7].

Core Viewpoint - Galapagos NV has completed the works council consultation process and will proceed with the wind-down of its cell therapy activities, impacting approximately 365 employees across multiple locations [1][2]. Group 1: Wind-Down Announcement - The decision to wind down cell therapy activities follows a strategic review and exploration of divestment options, with consultations in Belgium and the Netherlands now concluded [1][2]. - The wind-down will lead to the closure of sites in Leiden (Netherlands), Basel (Switzerland), Princeton and Pittsburgh (U.S.), and Shanghai (China) [2]. Group 2: Future Strategy - Post wind-down, Galapagos aims to reposition itself for long-term growth through transformative business development, maintaining operations at its headquarters in Mechelen, Belgium, and hubs in Chicago and San Francisco [3]. - The company will continue to manage non-cell therapy activities, including the TYK2 program GLPG3667, and will evaluate strategic alternatives for further development in severe auto-immune indications [3]. Group 3: Financial Position - As of December 31, 2025, Galapagos reported approximately €3.0 billion in cash and cash equivalents, and financial investments [4]. - The company plans to provide updates on the estimated timeline and costs associated with the wind-down during its full year 2025 earnings release on February 23, 2026 [4].

Core Insights - Galapagos NV (GLPG) presents a complex and uniquely positioned opportunity within the biotech sector, often evaluated through the lens of past clinical disappointments related to their early pipeline stages [1] Group 1: Company Overview - The company is viewed as a high-growth entity within a sector expected to experience exponential expansion [1] - Galapagos is associated with disruptive technologies and forward-thinking enterprises, indicating a focus on innovation [1] Group 2: Investment Approach - The investment strategy involves a combination of fundamental analysis and predictions of future trends, emphasizing the potential for substantial returns through innovation [1]

Core Insights - Galapagos NV (GLPG) presents a complex and uniquely positioned opportunity within the biotech sector, often evaluated through the lens of past clinical disappointments related to their early pipeline stages [1] Company Analysis - The company is viewed as a high-growth entity, operating in a sector that is expected to experience exponential expansion [1] - Galapagos is associated with disruptive technologies and forward-thinking enterprises, indicating a focus on innovation and substantial returns [1] Industry Context - The biotech industry has historically scrutinized Galapagos due to its clinical results, which may impact investor sentiment and future evaluations [1]